Overexpression of DJ-1 correlates with aggressive clinicopathological characteristics and poor prognosis in malignant tumors: a meta-analysis

Wang, Qingting; Li, Fangwei; Shi, Wenhua; Zhang, Qianqian; Wang, Jian; Yan, Xin; Chai, Limin; Li, Manxiang

doi:10.2147/ott.s162045

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22,23] The metaanalysis involved fourteen studies including 1,947 cancer patients and revealed that DJ-1 was an important biomarker in tumor evaluation and outcome. [24] The findings of our study provided that involvement in cyclin D1 and DJ-1, and in all the studied stages of PC compared to BPH. In addition, we found a significant association with the extent, the intensity, and overexpression of cyclin D1 and DJ-1 in PC, and BPH patients suggesting that they could be used as biomarkers for early detection of PC.…”

Section: Discussionsupporting

confidence: 50%

See 1 more Smart Citation

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Mohammed

Ibrahim

Atwa

et al. 2019

Forum of Clinical Oncology

View full text Add to dashboard Cite

BackgroundDisturbance in cell cycle regulatory genes is a common finding among many types of cancers. The aim of this study is to evaluate the role of cyclin D1 and DJ-1 in benign prostatic hyperplasia (BPH) and prostate cancer (PC).MethodThe current study enclosed 40 patients diagnosed with PC and 40 cases of BPH. The expression level of cyclin D1 and DJ-1 were evaluated by immunohistochemistry (IHC). Cyclin D1 scored depending on the percentage of stained nuclear tumor cells. While scoring of DJ-1 was based on intensity. The results were correlated with clinicopathological features and outcome.ResultsIn the PC group, cyclin D1 was detected in 95% and overexpressed in 42.5%, DJ-1 was positively stained in 85% and overexpressed in 47.5%. Meanwhile, in the BPH group, cyclin D1 was not detected and DJ-1 stained in only 2.5%. There was a statistically significant difference in Gleason score (GS), tumor stage, size, and treatment failure (p =< 0.001). In the terms of PC diagnosis prediction, although cyclin D1 was more specific (100%), DJ-1 is more sensitive than cyclin D1 (80%, 70%, respectively) (p = 0.000).ConclusionsCyclin D1 and DJ-1 may emerge as a promising way for diagnosis of PC in certain circumstances, as the presence of insufficient tissue sampling, small foci of carcinoma or benign lesions mimic PC. This is in addition to the known role of cyclin D1 and DJ-1 in PC prognosis.

show abstract

Section: Discussionsupporting

confidence: 50%

“…[17,26,27] On the other hand, this association was not proved in many earlier studies. [9,14,16,24,28] Sensible explanations were suggested to prove that these differences are sample size, technical varieties of biopsy taking, staining type (cytoplasmic vs nuclear) and scoring system.…”

Section: Discussionmentioning

confidence: 99%

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Mohammed

Ibrahim

Atwa

et al. 2019

Forum of Clinical Oncology

View full text Add to dashboard Cite

show abstract

Parkinson’s disease-associated 18 bp promoter variant of DJ-1 alters REST binding and regulates its expression

Pal

Roy

Chowdhury

et al. 2023

Neuroscience Letters

View full text Add to dashboard Cite

Correlation Among the Expression, Clinical Significance and Prognosis of DJ-1 and Runt-Related Transcription Factor 3 in Rectal Cancer

Zhang

Xue

et al. 2021

j biomater tissue eng

View full text Add to dashboard Cite

This study explored the correlation among the expression, clinical significance, and prognosis of DJ-1 and RUNX3 in rectal cancer. Eighty-five cases of resected rectal cancer tissue were obtained from patients treated from June 2014 to June 2015. The expression ofDJ-1 and RUNX3 mRNA was detected by reverse transcription-polymerase chain reaction (RT-PCR), and the expression of DJ-1 and RUNX3 protein was detected by immunohistochemistry. Their relationship to the clinicopathological features of the tumor was also analyzed. The correlation between the two proteins and survival prognosis [5-year disease-free survival(DFS)] was analyzed. RT-PCR results showed that the DJ-1 mRNA expression of cancer tissue increased, whereas that of RUNX3 decreased. Immunohistochemical results showed that the positive rate of DJ-1 protein of cancer tissue increased (69.41% vs. 21.18%), whereas that of RUNX3 decreased (40.00% vs. 77.65%). The positive expression of DJ-1 and RUNX3 was highly related to the cTNM staging of rectal cancer. Correlation analysis results showed a negative correlation between the genes in rectal cancer tissue. The follow-up records showed 5-year DFS data as follows: 50.00% for the DJ-1+/RUNX3− group, 57.14% for the DJ-1−/RUNX3− group, 71.43% for the DJ-1+/RUNX3+ group, and 82.50% for the DJ-1−/RUNX3+ group, suggesting that the 5-year DFS of the DJ-1+ group was lower, whereas that of the RUNX3+ group was higher. These results indicated that DJ-1 and RUNX3 were related to the occurrence, development, and progression of rectal cancer. Interestingly, there was a significant negative correlation between the genes, which was important for the treatment and prognosis of rectal cancer.

show abstract

Overexpression of DJ-1 correlates with aggressive clinicopathological characteristics and poor prognosis in malignant tumors: a meta-analysis

Cited by 4 publications

References 30 publications

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia

Parkinson’s disease-associated 18 bp promoter variant of DJ-1 alters REST binding and regulates its expression

Correlation Among the Expression, Clinical Significance and Prognosis of DJ-1 and Runt-Related Transcription Factor 3 in Rectal Cancer

Contact Info

Product

Resources

About